Eur Stroke J: Antithrombotic Therapy for secondary prevention of stroke or hyperpathic and non-valve atrial fibrillation patients with stroke and other thrombosis events

Patients with ischemic stroke or transient ischemic seizures and non-valve atrial atrial fibrillation had a higher risk of repeated stroke and other vascular eventsThis guide is intended to provide these patients with antithrombotic medications to advise on secondary prevention of stroke and other vascular outcomesworking group identified problems and results, graded evidence and developed recommendations based on the Recommendations Classification Assessment, Development and Evaluation Methodology and the European Stroke Organization (ESO) standard operating proceduresThe guidelines have been reviewed and approved by the ESO Guidelines Committee and the ESO Executive Committeefor patients with atrial fibrillation and pre-stroke or an over-the-counter ischemic attack, oral anticoagulants are more likely to reduce the risk of recurrence than antiplatelet or platelet-free treatmentCompared to vitamin K antagonists, non-vitamin K antagonists are preferred for oral anticoagulants because of their low risk of haemorrhage and deathFor the choice of treatment timing, patients who had previously had intra-brain haemorrhage (re-startoral anticoagulants), and treatment of older, cognitive lycite, renal insufficiency or subgroup of small vascular diseases, the recommendation for treatment timing was weak due to a lack of strong evidence, non-vitamin K antagonists oral anticoagulants are the preferred treatment for secondary prevention of stroke or thrombosis recurrence in patients with atrial fibrillation combined with ischemic stroke or transient ischemic attacksThe best time to initiate oral anticoagulants after acute ischemic stroke, whether or not patients with a history of cerebral hemorrhage should (re-start oral anticoagulants), and the best secondary preventive treatment for patients in specific subgroups require further study